chrisvoncsefalvay/vaers-outcomes huggingface dataset:
passed out/continued to drift in and out of conscientiousness; BP was very low; chest tightness; This is a spontaneous report from a non-contactable consumer (patient). A 54-year-old male patient received the second dose of  BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EP6955), via intramuscular route of administration on 09Apr2021 at 17:45 (at the age of 54 years) at a single dose in the left arm for COVID-19 immunization. Medical history included stroke/heart attack from 2014 to an unknown date. Concomitant medications included omeprazole (PROTONIX [OMEPRAZOLE]); atorvastatin calcium (LIPITOR [ATORVASTATIN CALCIUM]); levothyroxine sodium (LEVOTHYROXINE [LEVOTHYROXINE SODIUM]); amlodipine besilate, benazepril hydrochloride (AMLODIPINE BENAZEPRIL); citalopram; and clopidogrel. The patient previously took the first dose of BNT162B2 (lot number: EP6955) on 19Mar2021 (age: 54 years) in the left arm for COVID-19 immunization. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. It was unknown if patient was diagnosed with COVID-19 prior to vaccination. Patient had no known allergies. On 09Apr2021 at 18:00, after second vaccine was given, patient passed out. His wife was with him. He came to but continued to drift in and out of conscientiousness. His BP was very low, pulse ox 99. He also had chest tightness. Ambulance was called. He was stable till ambulance came and took him to hospital. The events resulted in emergency room/department or urgent care and hospitalization. Therapeutic measures were taken as a result of the events which included IV fluids, Tylenol and something was placed under his tongue for chest tightness. The patient had COVID test on an unspecified date with unknown results. The outcome of the events was recovering.  No follow-up attempts are possible. No further information is expected.
anterior thigh red, swollen, bruised approx 24 hr p/inj; tx ice, DPH & APAP
Pt received this vaccine despite her age being outside of guidelines for administration.  No adverse reactions noted.
Covid arm; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Covid arm) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (Covid arm). At the time of the report, VACCINATION SITE PAIN (Covid arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications provided. No treatment information provided.    This case was linked to MOD-2021-200520.
None   - Pt given Pediarix (Dtap, IPV, HepB) and Trihibit (Dtap, HIB) at the same time.
There is no adverse reaction or treatment. Didn't realize pt. was under 18. Father wanted his sons to get the vaccination here. We inquired about their age and he stated both were over 18. We didn't catch the dob on application.
Initial misuse report received from health care professional on 22 May 2014. A patient (gender not reported) had received 0.25 ml dose of FLUZONE on 14 January 2014 and 0.5 ml dose of FLUZONE on 12 January 2014, which led to extra dose of vaccination. No adverse event was reported. List of documents held by sender: None.
Significant (8cmm) erythema, induration and tenderness; fevers to 102, leukocytosis (20).
Received Pfizer-BioNTech vaccine on 1/26/21 and 2/16/21. Presented to ED with fatigue and shortness of breath. Was found to have a GI bleed and was tested for COVID-19 prior to admission to hospital for treatment. Was admitted from 3/22/21 to 3/27/21 and reported only mild COVID-19 symptoms during stay.
Sore throat, muscle aches, congestion, coughing.  (No fever, no nausea, no diarrhea). Typical "cold" symptoms.  Symptoms persisted for 2 full weeks, then much lighter but still some congestion and runny nose after 3 full weeks.
itchy; hives; This spontaneous case was reported by a patient and describes the occurrence of PRURITUS (itchy) and URTICARIA (hives) in a female patient of an unknown age who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    In 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In 2023, the patient experienced PRURITUS (itchy) and URTICARIA (hives). The patient was treated with ACRIVASTINE (BENADRYL [ACRIVASTINE]) at an unspecified dose and frequency and HYDROXYZINE HYDROCHLORIDE (ITERAX) at an unspecified dose and frequency. At the time of the report, PRURITUS (itchy) and URTICARIA (hives) had not resolved.        The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.  It was reported that patient had new vaccine a couple of weeks ago and about 2-3 days after she was feeling itchy all over. At the time of reporting she already consulted her doctor and was prescribed with Benadryl and Iterax but it was not working.
Patient at first felt an electric shock 15 min after she received the vaccine. Then when she arrived home felt very lethargic and took a nap. When she awoke, she felt feverish, couldn't move and very nauseated. She called 911 and went to the hospital where they gave her IV fluids and Zofran.
Patient experienced a slight fever. She could not sit up or walk without passing out. She stated that she passed out once. On 9.17.20 she said she felt ok, but weak. On 9.18.20 she said she was still feeling very weak.
Information has been received from a registered pharmacist concerning a patient who on 07-OCT-2008 was vaccinated subcutaneously with a 0.5 mL dose of VARIVAX (Oka/Merck) instead of ZOSTAVAX (Oka/Merck), due to pharmacy error.  No adverse effect was reported.  It is unknown if the patient sought medical attention.  Follow up information was received from the pharmacist who indicated that she did not want to provide additional information because the situation "has been taken care of".  No further information is available.
When he laid down and closed his eyes he saw a vivid bright yellow lighting line, on the back of his eyelids or brain.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program . The reporter is the patient.  A 71 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 30Mar2021 02:45 (Lot number: ER8732) at the age of 71 years as dose 1, single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: DIZZINESS (non-serious) with onset 30Mar2021 03:30, outcome "recovered" (30Mar2021), described as "When he laid down and closed his eyes he saw a vivid bright yellow lighting line, on the back of his eyelids or brain.". Therapeutic measures were not taken as a result of dizziness.  Additional information: No other products and investigation assessment were reported. Caller received his first Covid-19 vaccine today 30Mar2021 and wanted to report what he had experienced. He stated he had the really weirdest experience 45 minutes after receiving the vaccine. He stated when he laid down and closed his eyes he saw a vivid bright yellow lighting line, like a EKG signal turned vertical, coming down to the lower left line of a circle, it looked like a lightning bolt in it, like on the back of his eyelids or brain. Caller said he is fine and not experiencing anymore but it was about 45 minutes after his vaccine and lasting for about 5-10 minutes when he would close his eyes. When he would open his eyes, he felt fine. He stated it was a bizarre incident. He stated he did not know if Pfizer had put a biotech or biomarker in the vaccine that he had received today. Caller stated he was ok for Safety to contact him if there was a need to follow up about the report. No previous history of immunization with the Pfizer vaccine considered as suspect. No additional Vaccines Administered on Same Date of the Pfizer Suspect. He was not visited to emergency room and physician office. Prior Vaccinations (within 4 weeks) He was not administered any other vaccinations within four weeks prior to the first administration date of the suspect vaccine(s). No relevant tests were reported. No family history was reported. It was reported he just had 1st dose of covid vaccine. Had unusual experience after getting vaccine. Would like to talk to medical person about experience.  No follow-up attempts are possible. No further information is expected.
Fever, with weakness, headache the night of administration. Next day cough, headache. Seen by provider 4 days after vaccine admin/ cough, headache.
This case was reported by a consumer via call center representative and described the occurrence of arm discomfort in an adult patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received SHINGRIX at an unknown dose. On an unknown date, unknown after receiving SHINGRIX, the patient experienced arm discomfort. On an unknown date, the outcome of the arm discomfort was unknown. It was unknown if the reporter considered the arm discomfort to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but it was selected as an adult as per vaccine indication. The patient reported that she had issues with her arm after SHINGRIX vaccine. The information was provided via chat, which was transferred to GlaxoSmithKline representative prior to being able to document.
2-3 days after flu-mist had fever, malaise.  2 wks later Bilateral facial nerve palsy and peripheral neuropathy - ALL CONSISTENT WITH GUILLIAN-BARRE Medical records states facial paralysis, asthenia. msv
Chills-began at 10:00 am the next day and lasted until after I went to bed at 10:00 pm. No treatment Naseua- began at 10:00 pm the day of injection and lasted until 9:00 pm the following day. Treated with anti-naseua medication ondansetron. Swelling, redness, and pain at injection site-started the morning after injection and is still going on.
The patient arrived at the pharmacy at approximately 1:50 P.M. with complaints of difficulty breathing. The patient was in noticeable distress, displaying shortness of breath and difficulty breathing. The patient was very possibly experiencing an allergic reaction. I retrieved the epinephrine injection to deliver to the patient and asked my associates to call 911. I advised the patient I would be delivering the epinephrine injection and the patient verified understanding. I delivered the epinephrine injection in the patient's right thigh, and the patient displayed noticeable improvement in breathing. I advised the patient that one of my associates called 911, an ambulance was on the way, and would wait with the patient until emergency services arrived. Two EMTs arrived at approximately 2:00 P.M. and they asked me about the situation. I reported to one EMT I had delivered 1 epinephrine injection to the patient after she approached the pharmacy with symptoms, likely caused by a recent Shingrix vaccine I had delivered in the patient's right arm. The EMT examined the epinephrine injection I delivered and then he returned it to me. The EMTs cared for the patient and left the pharmacy area by 2:10 P.M.  I contacted the emergency room via telephone at approximately 2:48 P.M. to check on the patient's status. I spoke to a gentleman; he reported the patient was stable, the patient had not received another epinephrine injection since the injection I had delivered at approximately 1:50 P.M., and the patient's airway was not compromised. I thanked him for updating me on the situation and ended the telephone call.
Mom noticed reddened bumps on arms and back. They were itchy. None on anterior trunk Approx 15-20 eruptions. No treatment. No PCP.
Patient received Moderna COVID vaccine on 2/18/21 and 4/15/21. On 1/10/22, patient tested positive for COVID and admitted to our facility with acute hypoxic respiratory failure 88% on RA (seems to be related more to fluid overload/acute on chronic diastolic heart failure rather than COVID-19 pneumonia).  Patient missed HD as he did not want to pass on illness onto others so he's receiving HD while hospitalized. As of today (1/12/22), patient is still admitted in our med/surg unit.
pt recv vax 15MAR94 & 21APR94 pt exp joint pain & devel a pos rheumatoid factor; in f/u MD reported that the pt was vax 15MAR94; 1 wk later pt devel joint pain; Lab eval 20APR94 revealed rheumatoid factor 4.22, neg C-reactive protein;
This spontaneous report was received from a nurse and refers to a patient of an unknown age. No information regarding the patient's pertinent medical history, concomitant therapies, drug reactions and allergies were reported. On 06-OCT-2017, the patient was vaccinated with diluted with sterile diluent, expired M-M-R II injection powder (dose, route of administration were not reported; lot # L034730, expiration date 09-SEP-2017) for prophylaxis. Reporter stated that M-M-R II was supported by post expiry memo and did not have a previous temperature excursions. No adverse effects reported.
Itching, erythema, chills; low grade temperature. - Seen at urgent care Fri - symptoms onset Sat. am.
immediatley after injection my thyroid glands felt mildly enlarged but nothing serious. The next day I went to my routine allergy appointment and my dr was concerned that my breathing lung capacity was down 12% since my last test done three months ago. My lung capacity went from 63% to 51% and this was very concerning to me too. I have had asthma and my lung capacity at 63% for over ten years. The only thing I can relate it to is my COVID shots, since I know that the COVID virus is known to cause lung issues.
PATIENT HAD 2 MODERNA SHOTS AND WAS GIVEN A PFIZER VACCINE AS A THIRD DOSE
10 days post vaccine, 03/08/2021. I went to bed and could not sleep because I had a lot of pain. I could not settle into one position and last from the pain I was having. I had inflammation in both shoulders, both hips, elbows and wrist,  mostly my shoulder joints. The pain in the shoulders were 11 out 10. The doctor gave me anti-inflammatory medication for 10 days. It helped after 10 days, but it completely came back full strength. 10 days after the medication, I could not lift my arm. It sounded like SIRVA-shoulder injury related to vaccine administration. It seemed like they might have given my injection too deep and it irritated the bursa. Possibly because I am immune compromised. After the 10 days, the doctor said he could not help me more medication because he did not want to, but he gave me another 10 day anti-inflammatory. After the 2nd round, I still could not lift my arm. I cannot lift my arm, my deltoids were just off, both of them. Slowly the systemic response calmed down, but it took my shoulders longer to recover. It took about 3 months to really recover. It hurt for the 1st initial month but I could not function. I could not lift my arms. I saw a shoulder rehab and it took another couple of months to really recover from that. It took 2 months of rehab and a couple of other months to get my strength back, but yes, I have recovered. I want to ask CDC, because I suspect this is SIRVA, does the 2nd shot cover me? Should I go and get a booster. Should I write off the 2nd shot. I went to get a test to see if I had the antibodies, they said I did not. They said the test is kind of inconclusive.
HEADACHE ELEVATED TO MIGRAINE; SEVERE BODY ACHES; SEVERE FATIGUE; HEADACHE; NAUSEA; FEVER; BONE ACHE  IN LOW BACK, HIPS,BONES CONNECTING SPINE; FEELING DISORIENTED; NIGHT SWEAT; DIZZINESS AND LIGHT HEADED; LOSS OF APPETITE; UNABLE TO SLEEP; This spontaneous report received from a patient concerned a 40 year old female. The patient's height, and weight were not reported. The patient's past medical history included covid infection. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, and batch number: 203A21A expiry: UNKNOWN) dose was not reported, administered on 10-APR-2021 12:21 for prophylactic vaccination. No concomitant medications were reported. On JAN-2021, Laboratory data included: COVID-19 virus test (NR: not provided) unknown. On APR-2021, the subject experienced unable to sleep. On 10-APR-2021, the subject experienced feeling disoriented. On 10-APR-2021, the subject experienced night sweat. On 10-APR-2021, the subject experienced bone ache in low back, hips, bones connecting spine. On 10-APR-2021, the subject experienced dizziness and light headed. On 10-APR-2021, the subject experienced loss of appetite. On 10-APR-2021, the subject experienced headache. On 10-APR-2021, the subject experienced nausea. On 10-APR-2021, the subject experienced fever. On 10-APR-2021 15:21, the subject experienced severe fatigue. On 10-APR-2021 16:21, the subject experienced severe body aches. On 10-APR-2021 17:21, the subject experienced headache elevated to migraine. Laboratory data (dates unspecified) included: COVID-19 virus test (NR: not provided) positive, positive, positive. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from unable to sleep, feeling disoriented, night sweat, headache elevated to migraine, severe body aches, loss of appetite, headache, and fever, and bone ache in low back, hips, bones connecting spine on 12-APR-2021, and had not recovered from severe fatigue, dizziness and light headed, and nausea. This report was non-serious.
This case was reported by a consumer via call center representative and described the occurrence of rash in a patient who received PEDIARIX for prophylaxis. On an unknown date, the patient received PEDIARIX at an unknown dose. On an unknown date, unknown after receiving PEDIARIX, the patient experienced rash. On an unknown date, the outcome of the rash was unknown. It was unknown if the reporter considered the rash to be related to PEDIARIX. Additional details were provided as follows: The age at vaccination was reported. The patient demographic details and vaccine information were not reported. After vaccination, the patient experienced high intensity rash. The patient was taken to hospital for performed an allergy test. The physician would like to know, if the GlaxoSmithKline recommended an allergy test to the components of the vaccine. Lab Comments: On an unknown date, the patient performed allergy test in the hospital.
About 10 days after first COVID vaccine had episode of confusion and disorientation, went to a local hospital, had labs and CT and MRI, no cause found, went to neurologist, no cause found, went to cardiologist and wore monitor for 1 month, diagnosed with A Fib, 11 days after 3rd COVID vaccine experienced another episode, cardiologist visit made, states not cardiac problem,  to see neurologist,
4/14 9:00 am Pain and swelling at injection site (left arm). 4/14 4:30 pm Numbness of pinky and ring finger of left hand. 4/14 6:00 pm Fever 101.8°F until 4/18. 4/14 8:30 pm Dry cough fits until 4/18. 4/19 complete finger numbness persists.
achy legs/Sore arm; Weak; very tired; slight headache; This is a spontaneous report from a contactable nurse (patient). A 59-year-old female patient (no pregnancy) received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL1283), via an unspecified route of administration from 11Jan2021 at site of left arm at 14:45 at single dose for COVID-19 immunization. Medical history included multiple sclerosis and raynauds. The patient had known allergies: celecoxib (CELEXIA), amoxicillin, desipramine and pantoprazole. Concomitant medication included ascorbic acid, ergocalciferol, nicotinamide, retinol, riboflavin, thiamine hydrochloride (VITAMINS) and natalizumab (TYSABRI) from 30Dec2020. The patient received first dose of BNT162B2 with lot number: EH9899 on 21Dec2020 at 01:30 pm at site of left arm for COVID-19 immunization and experienced sore arm. The patient experienced achy legs at 06:00 on 12Jan2021, and weak and very tired that afternoon on 12Jan2021, slight headache. Much better 13Jan2021. Sore arm also developed on 12Jan2021. Facility type vaccine was in hospital. No other vaccine received within four weeks. No treatment for adverse event. No COVID prior vaccination. No COVID tested post vaccination. The outcome of events was recovered in Jan2021.
Complained about clogged ears (felt like she was under water), night vaccine was administered; hematoma (swollen); severe headache; thumb of the arm where shot was administered numb whenever patient bends her fingers (only happens) on left and right thumb, mostly left.
2 CM WHEAL, REDNESS, SOFT TO INJECTION SITE. DENIES PAIN, SHORTNESS OR BREATH AND CHEST PAIN UPON VISIT 8-17-11.
Participant indicated this is new or worsening symptoms related to VAERS ID. The intensity of the ringing and hum-like sound in both ears has worsened. It is slightly favoring the left ear. There is no way to treat tinnitus so I monitored it and got set up with an ENT. I was seen in February which is a 2 part visit. The first visit was virtual where they provided instructions on how to deal with it. I have an upcoming appointment on March 28, which will be a physical appointment where the doctors will come up with a treatment plan.
Fever, began approximately 16 hrs. after injection. Generalized convulsions, approximately 20 hrs. after injection, lasted about 3 minutes. Was seen in ER, then hospitalized.
Abdominal pain, nausea, vomiting, low grade fever, headache, body-aches, fatigue, joint pain, jaw pain, sharp chest pain when breathing and swallowing, etc.  Was seen in hospital ED on 3/14/2021.  Covid-19 tested negative on 3/14/2021.  Missed work two days.
Flu-like symptoms. Moderate chills, headache, body and muscle aches, very fatigued, very tender or soreness in UNDERARMS. Mostly gone about 18 hrs after they started. Had similar symptoms on the 2nd series of the shot but not quite as severe.
patient who is at the pharmacy today for their 2nd Moderna Covid-19 Vaccine after getting the 1st dose on 3May2021; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (patient who is at the pharmacy today for their 2nd Moderna Covid-19 Vaccine after getting the 1st dose on 3May2021) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (patient who is at the pharmacy today for their 2nd Moderna Covid-19 Vaccine after getting the 1st dose on 3May2021). At the time of the report, PRODUCT DOSE OMISSION ISSUE (patient who is at the pharmacy today for their 2nd Moderna Covid-19 Vaccine after getting the 1st dose on 3May2021) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications reported. No treatment reported
I received my vaccine and it was an immediate sharp pain in the arm. Then it went away and got better. Two weeks later, I started having other issues. I had really bad pain in the forearm in both arms, very uncomfortable and then it move up to my upper arms. All of this lasted for several days and hurts with movement. I have lost muscle strength and the use of my arms. I did not do anything to myself to cause the type of pain/injury I am experiencing. I visited my primary care doctor in January. I was referred to a neurologist in February and he ran several test. Now I am seeing another specialist and received a cortisone shot which hurt and it did not help with my symptoms.